Skip to main navigation
Top Links - Left
BioNTech.com
Newsroom
Investors
Healthcare Professionals
English
Language switcher (Content)
English
German
Top Links - Right
Connect
Main Navigation
BioNTech.com
News
Events & Presentations
Financials
Financials
SEC Filings
Annual Reports
Quarterly Reports
Financial Calendar
Corporate Governance
Corporate Governance
Overview
Transparency
ESG
Stock Info
Stock Info
Stock Quote & Chart
Analyst Coverage
Shareholder Fraud Warning
Share Repurchase Program
Dividend Information
Investor FAQs
Annual General Meeting
Annual General Meeting
Annual General Meeting 2024
Annual General Meeting Archive
Contact Us
Newsroom
Investors
Healthcare Professionals
Breadcrumb
Investors
Search
Search
Filter by content type
(-)
News
(48)
Filter by content year
2024
(2)
2023
(8)
2022
(8)
2021
(4)
2020
(26)
Filter by form group
Filter by category
(-)
Financial
(48)
(-)
Other
(48)
All
(40)
Events
(14)
Collaborators
(10)
Clinical
(1)
Filter by category
Search
News
BioNTech veröffentlicht Ergebnisse des dritten Quartals und Informationen zur Geschäftsentwicklung
News
BioNTech Announces Third Quarter 2020 Financial Results and Corporate Progress
News
BioNTech veröffentlicht Ergebnisse des Geschäftsjahres 2020 und Informationen zur Geschäftsentwicklung
News
BioNTech Announces Full Year 2020 Financial Results and Corporate Update
News
BioNTech veröffentlicht am 11. August 2020 Ergebnisse des zweiten Quartals 2020 sowie Informationen zum operativen Fortschritt
News
BioNTech to Report Second Quarter 2020 Financial Results and Operational Update on August 11, 2020
News
BioNTech veröffentlicht Ergebnisse des zweiten Quartals 2020 und Informationen zur Geschäftsentwicklung
News
BioNTech Announces Second Quarter 2020 Financial Results and Corporate Progress
News
Pfizer and BioNTech Announce Publication of Peer-Reviewed Data from Ongoing Phase 1/2 study of mRNA-based Vaccine Candidate, BNT162b1, Against SARS-CoV-2 in Nature
News
BioNTech and Fosun Pharma to Potentially Supply 10 Million Doses of BioNTech’s BNT162 mRNA-based Vaccine Candidate Against SARS-CoV-2 to Hong Kong SAR and Macao SAR
Pagination
Page 1
Next page
››